

Biosimilar medicines critical for future medicines access and sustainability but more biologic competition is needed in the EU

For Immediate Release

Date of release: 13 December 2023

By 2032, the biosimilar medicines contribution to health systems access and sustainability will soon match the impact of generic medicines. The number of biological medicines set to lose market exclusivity represents an opportunity for competition to free up invaluable resources for healthcare systems, to improve patient access and budget sustainability.

The 2023 update of the IQVIA report ‘The Impact of Biosimilar Competition in Europe’, presented today at the European Commission annual stakeholder event, describes the evolution of the biopharmaceutical market following the arrival of biosimilar competition in Europe.

It underlines the considerable cumulated clinical experience gathered with biosimilar medicines, reaching **5.8 billion patient treatment days**, and the considerable contribution of biosimilar medicines to healthcare sustainability with **€50 billion cumulated savings**. The widening of access inequity across EU member states, in spite of biosimilar medicines availability is a major concern which requires more multi-stakeholder policy work to benefit from the next wave of biologic Loss of Exclusivity.

Commenting ahead of the [European Commission meeting](#), Julie Maréchal-Jamil, Director of Biosimilars Policy & Science at Medicines for Europe, said: *“Today, the positive contribution of biosimilar medicines to availability, affordability, accessibility and innovation needs no further demonstration. With the next wave of biotechnological medicines around the corner, we need a fundamental redirection of regulatory and market approaches if we want to expand patient access to more biologic medicines. Coordinated action at EU and national level can undoubtedly contribute to address today’s disparities and changing dynamics.”*

The annual [European Commission multistakeholder biosimilar event](#) offers a unique opportunity for open and constructive dialogue among actors of the biosimilar field and acts as reference point for the European biosimilar policy agenda.

The Biosimilar medicines group

The Biosimilar Medicines Group is a sector group of Medicines for Europe representing the leading companies developing, manufacturing and/or marketing biosimilar medicines across Europe. With more than 15 years of positive patient treatment experience, biosimilar medicines today provide a huge opportunity to deliver significantly improved access to modern therapies for millions of European patients in both chronic and acute care. Our members bring competition to the biological medicines market, thereby increasing access to highly innovative treatments to patients in Europe and around the world, and supporting the sustainability of the European healthcare systems.